Polymyositis Treatment & Management
- Author: Ramesh Pappu, MD, DPH, MBBS; Chief Editor: Herbert S Diamond, MD more...
Treatment of polymyositis (PM) is empirical because of the rarity of the disease and the paucity of randomized, controlled trials.
Prednisone is the first-line treatment of choice for polymyositis. Typically, the dose is 1 mg/kg/day, either as a single or divided dose. This high dose is usually continued for 4-8 weeks, until the creatine kinase (CK) level returns to reference ranges. Taper prednisone by 5-10 mg on a monthly basis until the lowest dose that controls the disease is reached.
Monitor response to therapy based on improvement in muscle strength and muscle endurance and decrease in CK levels. Closely monitor patients with polymyositis for disease activity and adverse effects of corticosteroids, such as weight gain, hypertension, osteopenia, and steroid myopathy.
Corticosteroid myopathy can occur during the course of treatment and must be distinguished from reactivation of muscle disease. CK level is usually within reference ranges in patients with steroid myopathy. No improvement is observed with raised doses of steroids, and the condition worsens if the dose is increased.
Immunosuppressive agents are indicated in patients who do not improve with steroids within a reasonable period (ie, 4 wk) or in whom adverse effects from corticosteroids develop. Patients with poor prognostic indicators, such as dysphagia or dysphonia, are likely to require immunosuppressive agents. Under these circumstances, methotrexate is the second-line agent. Patients with inclusion body myositis usually respond poorly to corticosteroids and immunosuppressive agents.
Obtain baseline liver function tests and pulmonary functions before initiating immunosuppressive therapy. Azathioprine, cyclophosphamide, chlorambucil, and cyclosporine have been used with varying success as second-line agents for polymyositis.
Intravenous immunoglobulin (IVIG) has been used for the short-term treatment of steroid-resistant cases of polymyositis.[13, 14]
The role of newer agents, such as tumor necrosis factor (TNF) inhibitors, remains unclear. Case reports describe successful use of the TNF inhibitor infliximab in refractory cases, but small clinical trials have yielded mixed results, with clinical flares occurring in some patients.[15, 16, 17, 18] A small trial of the TNF inhibitor etanercept provided encouraging results.
The anti-CD20 monoclonal antibody rituximab may be a new approach to therapy for refractory cases. The benefit of rituximab was demonstrated in the Rituximab in Myositis (RIM) study, the largest randomized trial ever completed in myositis. RIM included 200 patients with polymyositis, dermatomyositis, or juvenile dermatomyositis not controlled by corticosteroids and other immunosuppressive agents.
The study had a placebo phase design in which half the patients received two rituximab infusions at baseline, whereas the other half received rituximab 8 weeks later. At a median of approximately 20 weeks, 83% of study subjects receiving rituximab met the International Myositis Assessment and Clinical Studies Group preliminary definition of improvement. Whether rituximab was received early or late made no significant difference in the time to achieve the definition of improvement.
The calcineurin inhibitor tacrolimus appears to be effective, safe, and well tolerated in patients with polymyositis that is refractory to other treatments. In a systematic review, CK levels patients decreased in all patients treated with tacrolimus, the average glucocorticoid dosage was reduced from 33.8 to 11.5 mg/day, and the majoriy of patients showed improvement in muscle strength and physical function status. However, randomized, controlled trials of tacrolimus in poymyositis have yet to be conducted.
Patients with polymyositis may benefit from a high-protein diet. Monitor patients to avoid excessive weight gain due to corticosteroid use.
Encourage patients with polymyositis to start a supervised exercise program early in the disease course. During the acute stage of polymyositis, patients may benefit from heat therapy, passive range-of-motion exercises, and splints to avoid contractures.
Once acute inflammation is under control, the rehabilitation program should include active range-of-motion exercises and isometric contractions of the muscle groups. With improvement in muscle strength, patients should perform isotonic exercises with light resistance. Encourage patients to do 15-30 minute sessions of aerobic exercise when the disease is inactive.
A neurologist or rheumatologist is the primary consultant. Consultation may also be required with the following specialists:
Speech therapists (for swallow evaluation)
Extramuscular Manifestations of Polymyositis
Treatment of extramuscular manifestations of polymyositis includes the following:
Constitutional symptoms, such as fever and fatigue - Usually respond to corticosteroids
Articular symptoms of polymyositis - Usually resolve with treatment of the myositis; some patients develop a rheumatoidlike arthropathy, which may require immunosuppressive treatment such as methotrexate
Severe interstitial lung disease - May benefit from high-dose steroids and immunosuppressive treatment, especially cyclophosphamide; in a study of 14 patients with dermatomyositis and acute interstitial pneumonia treated with infliximab, Chen et al reported satisfactory relief in the 10 patients given early treatment but treatment failure and death in those treated late 
Cardiac abnormalities - May respond to corticosteroids; symptomatic arrhythmias require antiarrhythmic therapy, and symptomatic heart block is treated with placement of a pacemaker
Dysphagia secondary to cricopharyngeal involvement in polymyositis/dermatomyositis is a rare manifestation and usually reflects poor prognosis. Dysphagia responds either slowly or poorly to immunosuppressive therapies or high-dose corticosteroids. A large case series indicated that treatment with IVIG can be effective in patients with steroid-resistant esophageal manifestations of polymyositis/dermatomyositis.
Dysphagia may be severe enough to require enteral feeding through a gastrostomy tube or parenteral nutrition.
Inpatient and Outpatient Care
Patients with polymyositis should be closely monitored in the hospital while they are taking high-dose corticosteroids. Ideally, skin testing for tuberculosis should be performed before initiation of corticosteroid treatment.
Serial creatine kinase (CK) levels should be monitored to assess improvement. Severe pulmonary or cardiac involvement may require management in an intensive care setting. In patients treated with immunosuppressive agents, regularly monitor CBC, liver function test findings, and renal function. Patients with polymyositis usually need aggressive inpatient physical therapy.
Patients with polymyositis should be seen every 2-3 weeks initially; if they are stable, they should be seen at monthly intervals thereafter.
Frequently check laboratory tests, including CK, and document muscle strength evaluation results. Check patients' weight during each visit. Routine age-appropriate cancer screening is recommended. Arrange outpatient physical therapy.
Deterrence and Prevention
The following precautions can aid against complications associated with polymyositis or its treatment:
Raynaud phenomenon - Patients with polymyositis should avoid cold exposure if Raynaud phenomenon is a significant problem
Esophageal involvement - Patients with esophageal involvement can elevate the head of the bed and avoid eating before bedtime to minimize reflux and risk of aspiration; histamine 2 receptor antagonists, proton pump inhibitors, and/or prokinetic agents may be useful in patients with esophageal reflux and dysmotility.
Osteoporosis - Prescribe calcium with vitamin D supplementation and oral bisphosphonates for osteoporosis prophylaxis
Bohan A. History and classification of polymyositis and dermatomyositis. Clin Dermatol. 1988 Apr-Jun. 6(2):3-8. [Medline].
Zampieri S, Valente M, Adami N, et al. Polymyositis, dermatomyositis and malignancy: a further intriguing link. Autoimmun Rev. 2010 Apr. 9(6):449-53. [Medline].
Lee CW, Muo CH, Liang JA, Sung FC, Hsu CY, Kao CH. Increased osteoporosis risk in dermatomyositis or polymyositis independent of the treatments: a population-based cohort study with propensity score. Endocrine. 2015 Oct 1. [Medline].
Marie I, Hachulla E, Chérin P, et al. Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum. 2005 Apr 15. 53(2):155-65. [Medline].
Rai SK, Choi HK, Sayre EC, Aviña-Zubieta JA. Risk of myocardial infarction and ischaemic stroke in adults with polymyositis and dermatomyositis: a general population-based study. Rheumatology (Oxford). 2015 Sep 30. [Medline].
Yang Z, Lin F, Qin B, Liang Y, Zhong R. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol. 2015 Feb. 42 (2):282-91. [Medline].
Carruthers EC, Choi HK, Sayre EC, Aviña-Zubieta JA. Risk of deep venous thrombosis and pulmonary embolism in individuals with polymyositis and dermatomyositis: a general population-based study. Ann Rheum Dis. 2014 Sep 5. [Medline].
Bronner IM, van der Meulen MF, de Visser M, Kalmijn S, van Venrooij WJ, Voskuyl AE, et al. Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis. 2006 Nov. 65(11):1456-61. [Medline]. [Full Text].
Schnabel A, Hellmich B, Gross WL. Interstitial lung disease in polymyositis and dermatomyositis. Curr Rheumatol Rep. 2005 Apr. 7(2):99-105. [Medline].
Kuo SH, Vullaganti M, Jimenez-Shahed J, Kwan JY. Camptocormia as a presentation of generalized inflammatory myopathy. Muscle Nerve. 2009 Dec. 40(6):1059-63. [Medline].
Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology. 2008 Feb 5. 70(6):418-24. [Medline].
Cherin P, Pelletier S, Teixeira A, et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum. 2002 Feb. 46(2):467-74. [Medline].
Kumar A, Teuber SS, Gershwin ME. Intravenous immunoglobulin: striving for appropriate use. Int Arch Allergy Immunol. 2006. 140(3):185-98. [Medline].
Hengstman GJ, van den Hoogen FH, Barrera P, Netea MG, Pieterse A, van de Putte LB, et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol. 2003. 50(1):10-5. [Medline].
Anandacoomarasamy A, Howe G, Manolios N. Advanced refractory polymyositis responding to infliximab. Rheumatology (Oxford). 2005 Apr. 44(4):562-3. [Medline].
Aggarwal R, Oddis CV. Therapeutic advances in myositis. Curr Opin Rheumatol. 2012 Nov. 24(6):635-41. [Medline].
Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Helmers SB, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis. 2008 Dec. 67(12):1670-7. [Medline].
Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013 Feb. 65(2):314-24. [Medline]. [Full Text].
Alexanderson H. Exercise: an important component of treatment in the idiopathic inflammatory myopathies. Curr Rheumatol Rep. 2005 Apr. 7(2):115-24. [Medline].
Chen D, Wang XB, Zhou Y, Zhu XC. Efficacy of infliximab in the treatment for dermatomyositis with acute interstitial pneumonia: a study of fourteen cases and literature review. Rheumatol Int. 2013 Oct. 33(10):2455-8. [Medline].
Marie I, Menard JF, Hatron PY, et al. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients. Arthritis Care Res (Hoboken). 2010 Dec. 62(12):1748-55. [Medline].
Milisenda JC, Selva-O'Callaghan A, Grau JM. The diagnosis and classification of polymyositis. J Autoimmun. 2014 Feb-Mar. 48-49:118-21. [Medline].
Uthman I, El-Sayad J. Refractory polymyositis responding to infliximab. Rheumatology (Oxford). 2004 Sep. 43(9):1198-9. [Medline].
Ge Y, Zhou H, Shi J, Ye B, Peng Q, Lu X, et al. The efficacy of tacrolimus in patients with refractory dermatomyositis/polymyositis: a systematic review. Clin Rheumatol. 2015 Sep 2. [Medline].